All In Biotech

Drug Trial Radar · NCT04282954

Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

A Randomized, Double-blind, Active-controlled, Multi-center Phase II Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

Last checked: Nov 19, 2026Latest source record: Jul 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 188 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

188

Actual

Start

Nov 15, 2019

Primary completion

Oct 20, 2020

Study completion Dec 11, 2020

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Feb 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical trial to evaluate the safety and efficacy of JP-1366 in patients with erosive gastroesophageal reflux disease

Conditions

  • GERD

Interventions

  • JP-1366Drug

    JP-1366, QD

  • JP-1366 placeboDrug

    JP-1366 placebo, QD

  • Esomeprazole 40mgDrug

    Esomeprazole 40mg, QD

  • Esomeprazole placeboDrug

    Esomeprazole placebo, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Accumulated mucosal defect cure rate*(%) at Week 8 following study drug administration (%)Time frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Severance Hospital and 19 hospitals

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.